Edition:
United Kingdom

Seres Therapeutics Inc (MCRB.OQ)

MCRB.OQ on NASDAQ Stock Exchange Global Select Market

10.19USD
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
$10.19
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
63,921
52-wk High
$17.33
52-wk Low
$8.86

Chart for

About

Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company's drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on... (more)

Overall

Beta: --
Market Cap(Mil.): $482.91
Shares Outstanding(Mil.): 40.51
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Seres Therapeutics Announces FDA Orphan Drug Designation For SER-287 In Treatment Of Pediatric Ulcerative Colitis

* SERES THERAPEUTICS ANNOUNCES FDA ORPHAN DRUG DESIGNATION FOR SER-287 IN TREATMENT OF PEDIATRIC ULCERATIVE COLITIS

04 Dec 2017

BRIEF-Seres Therapeutics Q2 net loss $28 million

* Seres therapeutics reports second quarter 2017 financial results and provides update on operational progress

03 Aug 2017

BRIEF-Seres Therapeutics appoints Willard Dere to Board of Directors

* Seres Therapeutics strengthens board of directors with appointment of Willard Dere, M.D., former Amgen Chief Medical Officer Source text for Eikon: Further company coverage:

10 Jul 2017

Earnings vs. Estimates